Scynexis Inc
$ 4.23
-0.35%
12 Jun - close price
- Market Cap 336,042,000 USD
- Current Price $ 4.23
- High / Low $ 4.42 / 4.21
- Stock P/E N/A
- Book Value 0.67
- EPS -3.84
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.53 %
- 52 Week High 10.48
- 52 Week Low 4.15
About
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
Analyst Target Price
$33.55
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-04 | 2025-11-05 | 2025-08-14 | 2025-05-16 | 2025-03-12 | 2024-11-05 | 2024-08-07 | 2024-05-08 | 2024-03-29 | 2023-11-12 | 2023-08-13 |
| Reported EPS | -0.418 | 2 | -0.17 | -0.14 | -0.11 | -0.09 | -0.06 | -0.3 | 0.01 | -0.39 | -0.04 | 2.46 |
| Estimated EPS | 0.1267 | 1.0133 | -0.2 | -0.2 | -0.2 | -0.02 | -0.07 | -0.2 | -0.2 | -0.2 | -0.15 | 1.55 |
| Surprise | -0.5447 | 0.9867 | 0.03 | 0.06 | 0.09 | -0.07 | 0.01 | -0.1 | 0.21 | -0.19 | 0.11 | 0.91 |
| Surprise Percentage | -429.9132% | 97.3749% | 15% | 30% | 45% | -350% | 14.2857% | -50% | 105% | -95% | 73.3333% | 58.7097% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SCYX
2026-06-04 06:10:51
The article provides a financial overview of SCYNEXIS, Inc. (TRADEGATE:135), focusing on its pretax income. It indicates that the market for this stock is currently closed. The content is primarily a data page from TradingView, offering financial information and market data without in-depth analysis.
2026-06-04 05:09:21
This article provides a very brief financial snapshot for SCYNEXIS, Inc. trading on the Munich Stock Exchange under the ticker 135. It specifically mentions "Total liabilities" but does not offer any specific figures or details beyond that. It appears to be a stub or a section heading within a larger financial overview on TradingView.
2026-06-04 05:09:21
This article provides key balance sheet information for SCYNEXIS, Inc. (MUN:135), detailing the company's financial position as of Q1 26. It highlights that total assets increased to ‪67.19 M‬ EUR, a 33.69% rise from Q4 25, while total liabilities significantly increased by 282.56% to ‪31.43 M‬ EUR in the same period. The data is available on TradingView, covering various financial metrics over several years.
2026-06-04 03:41:19
The article focuses on the "Net debt" section for SCYNEXIS, Inc. (FWB:135) on TradingView. It appears to be a financial data page providing an overview of the company's financial performance, specifically highlighting its net debt over different periods. The content itself seems to be the infrastructure and boilerplate of a financial data website rather than a detailed analysis.
2026-06-03 19:11:13
This article provides financial information for SCYNEXIS, Inc. (TRADEGATE:135), specifically focusing on its working capital per share. It appears to be a data point or a section from a larger financial overview on TradingView, indicating the value and changes in working capital per share for the company.
2026-06-03 14:40:05
This article provides details on the cash flow of SCYNEXIS, Inc. (FWB:135), focusing on its operating, investing, and financing activities. It states that the free cash flow for Q1 2026 was -7.01 million EUR, and for 2025, it was -4.50 million EUR, with operating cash flow also at -4.50 million EUR for 2025. The data presented covers a period from 2012 to 2025, indicating historical trends in cash flow metrics.
